<DOC>
	<DOCNO>NCT01857362</DOCNO>
	<brief_summary>The purpose study evaluate bioequivalence Orfadin 20 mg 10 mg capsule healthy volunteer .</brief_summary>
	<brief_title>Bioequivalence Orfadin 20 mg Compared Orfadin 10 mg Capsules .</brief_title>
	<detailed_description>This open , randomized 2-way crossover study 12 healthy volunteer . Subjects receive single oral 20 mg dos nitisinone administrate one 20 mg capsule two 10 mg capsule Orfadin . There 3-week washout period dos . There screen visit within 3 week prior first dose . During treatment period , subject admit clinic afternoon day drug administration ( i.e. , Day -1 ) remain clinic 48-hour post-dose blood sample collect morning Day 3 . They return ambulatory visit morning Day 4 ( 72-hour sample ) . A follow-up visit take place 7-14 day last dose .</detailed_description>
	<mesh_term>Nitisinone</mesh_term>
	<criteria>Healthy male female volunteer 1855 year age , inclusive . BMI 18,530,0 kg/m2 , inclusive . Subjects current keratopathy , abnormality find slitlamp examination . Subjects heavy smoker consume 5 cup coffee per day . Subjects history drug and/or alcohol abuse positive drug screen alcohol breath test . Subjects positive screen hepatitis B surface antigen , hepatitis C antibodies human immunodeficiency virus ( HIV ) 12 antibody . Subjects enrol another concurrent clinical study intake investigational medicinal product within three month prior inclusion study . Subjects donate 50 mL blood within 60 day prior drug administration donate 1,5 liter blood 10 month prior first drug administration . Female subject pregnant breastfeeding . Female subject childbearing potential male subject must willing use effective form contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Orfadin</keyword>
	<keyword>Nitisinone</keyword>
	<keyword>Bioequivalence</keyword>
</DOC>